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Ⅰ．Introduction
 During orthopedic surgery for conditions such as 
fracture or unstable spinal pathologies, stabilization of 
unstable segments is one the most important aspects of 
the treatment strategy. Arthrodesis surgery is one of the 
most viable options to achieve this stability［1-3］. 
 Postoperative bone union can take from a few weeks 
to 1 year and, occasionally, delayed or inadequate bone 
union can cause pseudarthrosis, which in turn can lead 
to adverse outcomes such as chronic instability and pain, 
resulting in a poor quality of life. Thus, acceleration of 
postoperative bone union is required for an effective 
arthrodesis surgery.
 Platelet-rich plasma （PRP） is known to accelerate 
tissue healing and has already been introduced in the 
field of plastic surgery, dentistry, and orthopedics
［4-8］. Additionally, we have reported on its clinical 
usefulness in spinal fusion surgery with a 2-3 month 
earlier bone fusion［9-12］. Basic studies also show 
that PRP administration in rat models of spinal fusion 
led to a significantly faster bone union without any 
complications［9,10］. However, one of the possible 
barriers to the clinical applications of fresh PRP is its 
short half-life of merely several hours. To overcome 
such issues, the use of freeze-dried PRP （FD-PRP） 
has been suggested and developed［13］. In the current 
article, we reviewed the biological features of FD-PRP, 
confirmed by in vivo and in vitro animal experiments by 
introducing our associated basic studies. 
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Abstract
Platelet-rich plasma （PRP） has been reported to accelerate bone union in spinal fusion surgery 
in a clinical situation as well as a rat experimental model. However, one of the major issues with fresh 
PRP is its short half-life, of only several hours. To overcome this problem, the use of freeze-dried PRP 
（FD-PRP） and its efficacy in bone union in vivo and in vitro have been investigated. Using a rat model 
of spinal posterolateral fusion （PLF）, we showed that the ability of FD-PRP to accelerate bone union is 
comparable to that of fresh PRP and BMP （human recombinant bone morphogenetic protein 2）. FD-PRP 
has the ability to remodel the bone with thinner and tangled trabecular bone with confirmed rigidity. In 
conclusion, FD-PRP has a bone union ability comparable to that of fresh PRP and BMP and thus, together 
with its safety and more affordable price, could be an adequate alternative to fresh PRP and BMP. 
　Key words:  Platelet-rich plasma （PRP）, freeze-drying, spinal fusion, bone union, platelet-derived 
growth factor （PDGF）
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Basic experimental conditions and Ethics issues in the 
related researches
 Basic experiments included in the current review 
article used male Sprague-Dawley rats or partly human 
blood samples. All of the protocols for experimental 
procedures were approved by the ethics committees of 
our institution and followed the National Institutes of 
Health Guidelines for the Care and Use of Laboratory 
Animals （2010 revision）.
Fresh- and FD-PRP preparation and biological 
properties［14-16］
 PRP has been reported to contain a large number of 
growth factors and to have a role in promoting tissue 
regeneration［17-19］. In our previous studies, we 
evaluated and confirmed the biological properties of 
fresh- and FD-PRP. Fig. 1 shows how fresh PRP and 
FD-PRP are prepared using human autologous whole 
blood［20］. 
 The procedure for PRP preparation using animals 
was as follows: after the donor rats were anesthetized, 
fresh whole blood was obtained transcardially and 
centrifuged at 1500 rpm for 10 minutes. Subsequently, 
the plasma fraction was separated from the red blood 
cells and further centrifuged at 3000 rpm for 10 
minutes to pellet the platelets as previously described. 
Pelleted platelets were collected and separated from 
the supernatant platelet-poor plasma （PPP）. PRP was 
generated by mixing the platelets with 2.5-mL PPP. 
Test tubes containing aliquoted PRP were then rotated 
in an ethanol bath at －60℃ for membranous freezing 
（preliminary freezing） and then immediately frozen at 
－30℃ for 4 h. Tubes were then attached to a vacuum 
freeze-dryer to complete the process and stored for 8 
weeks at 4℃ to maintain FD-PRP in a powdery state
［16］. Prior to the experiments, we resuspended FD-
PRP powder in distilled water. To avoid any changes in 
component concentrations, the weight after dissolving 
was matched to the weight before freeze-drying. FD-
PRP was activated by adding calcium chloride solution 
and thrombin solution to the sample. 
 One of the studies showed that FD-PRP contained 
a significant number of platelets, in fact 4.9 times 
that of whole blood［16,20］. Furthermore, enzyme-
linked immunosorbent assay （ELISA） showed that 
concentrations of platelet-derived growth factor BB 
（PDGF-BB） and transforming growth factor β1 （TGF-
β1） were significantly higher in fresh PRP and FD-PRP 
than in whole blood［16］. 
Ⅱ． In vivo evaluation of the efficacy of FD-
PRP in bone fusion in animal lumbar 
posterolateral fusion models［16］
 The efficacy in bone fusion was confirmed using 
animal spinal fusion models［16］. Posterolateral fusion 
（PLF） was performed in rats （Fig. 2） and then animals 
were divided into five experimental groups: one sham 
group and four experimental groups identified by the 
graft materials: artificial bone group （artificial bone－
alone）, autologous bone group, FD-PRP （artificial 
bone＋FD-PRP） group, and human recombinant bone 
morphogenetic protein 2 （BMP）＋artificial bone group 
as a positive control［16］. Refit® （Hoya Corporation, 
Tokyo, Japan） was used as the artificial bone graft 
substitute, which is also used in clinical spine surgery. 
Fig. 1　PRP preparation using human blood［20］.
（a）  PRP was sequestrated from the supernatant of the 
centrifuged whole blood.
（b） PRP frozen at －80℃
（c, d）Freeze-dried PRP was made into powder form using 
a freeze dryer
(a)
(b)
(c)
(d)
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The FD-PRP group used a mixture of 0.5 mL Refit and 
0.5 mL gelled-activated FD-PRP （Figs. 2 （b） and 2 
（c））. In the BMP group, 0.5 mL Refit and 5 μg of BMP 
（Sigma-Aldrich Corporation, St. Louis, MO, USA） 
were mixed and transplanted［21,22］. In the autologous 
bone group, rats were implanted with ground spinous 
processes of T10-L2. The posterolateral lumbar spine 
in each rat was exposed through a midline skin incision, 
followed by two paramedian fascial incisions to expose 
the lamina and the transverse processes of L4-L6 （Fig. 
2 （d））.
　Radiological evaluation showed that FD-PRP 
combined with artificial bone significantly accelerated 
bone fusion comparable to BMP （Fig. 3）. Histological 
evaluation showed trabecular bone formation with a 
more tangled bony structure and many thin branches at 
the early stage of 4 weeks after surgery with comparable 
rigidity to autologous bone, indicating that bone fusion 
induced using FD-PRP showed different structure in 
bone fusion （Fig. 4）. Biomechanical tests showed that 
the harvested spinal column from the FD-PRP group 
showed significantly stronger rigidity compared to that 
of the artificial bone–alone group and slightly inferior, 
although not significantly, compared to the autologous 
bone group （Fig. 5）. Thus, FD-PRP enables earlier bone 
union with an increased amount of bone formation and 
trabecular bone remodeling with considerable rigidity.
(C)
L4
L5
L6
PRP
)D()B()A(
Fig. 2
（a）  FD-PRP preparation［16］. FD-PRP is in powder form 
and can be dissolved in distilled water to the same 
concentration of fresh PRP. 
（b） Artificial bone is crushed into powder. 
（c）  FD-PRP is mixed with the powdered artificial bone, 
followed by activation using thrombin and calcium 
chloride before use. 
（d）  Schema of the spine （transplantation site）. The graft 
material was implanted over the transverse processes 
of L4-L6.
Fig. 4　Histological images of trabecular bone［16］. 
（a） Artificial bone－alone group
（b） Autologous bone group
（c） Artificial bone＋fresh PRP group
（d） Artificial bone＋FD-PRP group
（e） Artificial bone＋BMP group
　Trabecular bone formation of the FD-PRP group 
consisted of a tangled structure with more thin branches, 
compared to the autologous bone group. Trabecular bone 
formation is similar to that of the BMP group.
Fig. 3　 Anteroposterior radiographs of the spinal segment 
of the platelet-rich plasma group 4 weeks after 
surgery［16］. 
（a） Sham group
（b） Artificial bone－alone group
（c） Autologous bone group
（d） Artificial bone＋FD-PRP group
（e） Artificial bone＋BMP group
　FD-PRP and BMP groups showed greater bone 
formation compared with the autologous bone group.
(a) (b) (c)
(e) (f)(c)
(a) (b)
(c) (d)
50μm
(e)
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Ⅲ． Biological activity of long-term-stored 
FD-PRP［20］
 Previous work shows that the activity of FD-PRP 
is maintained after an 8-week long-term-storage［20］. 
PRP prepared from human whole blood was tested to 
assess its platelet activation features as well as growth 
factor content after 8-week preparation［20］. Assessment 
of activated platelets using flow cytometry showed a 
platelet activation of about 80%, which did not differ 
between the freeze-drying and pre-activation conditions 
（Fig. 6）［20］. An antibody array detected growth factors 
such as PDGF （AA, AB, BB）, IGFBP-2, VEGF, TGF-ß, 
EGF and M-CSFR in fresh PRP （Fig. 7 （a））. If stored 
at room temperature for 8 weeks, almost none of the 
growth factors were detected （Fig. 7 （b））. However, 
thinner but significant spots were detected in the PRP 
frozen after preparation （Fig. 7 （c））. Results showed 
that in FD-PRP, almost all growth factors were preserved 
to a considerable level compared with those in fresh 
PRP （Fig. 7 （d））. These assays showed that storage of 
PRP at room temperature led to a significant decrease 
in platelet count while frozen/freeze-drying maintained 
it for about 8 weeks. Platelet activation properties were 
also maintained when the activated PRP was stored in 
frozen or free-dried states. Compared with the frozen 
PRP, the FD-PRP showed a more significant preservation 
of growth factors, comparable to that of the fresh one. 
In vitro evaluation using osteoblasts
 We also reported that PDGFs in FD-PRP retain their 
activity, promoting the proliferation of osteoblasts via 
the PDGFR-mediated ERK signaling pathway. This 
activity is preserved even after freeze drying and 4-week 
storage, resulting in two-fold proliferation of osteoblasts
［15］. 
Fig. 5　 Mechanical strength evaluation: three-point 
bending test［16］. 
（a） Harvested lumbar spine （L4-L6）
（b） Three-point bending 
（c）  Representative plotting for initial peak pressure 
measurement.
Fig. 7　 Growth factor detection using antibody arrays
［20］.
（a） Fresh PRP
  　Growth factors such as PDGF AB, VEGF R2, 
TGF-β, and EGF were detected as spots. Each 
detailed location is shown in the scheme.
（b） PRP in RT stored for 8 weeks
 　Almost all growth factors disappeared.
（c） Frozen PRP stored for 8 weeks
 　Thinner but significant spots were detected.
（d） Freeze dried PRP stored for 8 weeks
  　Almost all growth factors were observed as robust 
spots.
(A)
(B)
(C)
Fig. 6　 Assessment of activated platelets using flow 
cytometry. X axis represents anti-CD41a antibody 
（platelet marker） and the Y axis represents anti-
CD62P antibody （marker for activated platelets）
［20］.
（a）  Fresh PRP immediately after preparation （before 
activation）.
（b） Activated fresh PRP  
（a, c） Activated freeze dried PRP （8 weeks after 
preparation） 
　The percentages of activated platelets in freeze dried 
samples after 8 weeks were almost the same as in fresh 
PRP.
2.1?
97.9???? 84.8?
15.2??????? 83.1%16.9%
(c) (d)(b)
(a)
PDGF AB
TGF-β
VEGF R2
EGF
(scheme)
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Ⅳ．Safety and availability of PRP
 The fact that FD-PRP showed comparable bone 
union ability to that of BMP is important, particularly 
given that BMP is expensive, and thus unavailable 
in some countries, as well as the fact that it has 
associated risks such as tumor formation and excessive 
inflammation［23-25］. Compared to BMP, PRP is safer 
because it is made from autologous blood and its clinical 
use has few significant complications［6］. Considering 
that growth factors are still preserved in the long-term 
stored FD-PRP, it should be useful if it is prepared 
before the surgery, or even if it is made from other 
origins such as induced pluripotent stem cells.
 In conclusion, FD-PRP shows potential for the 
purpose of accelerating bone union, derived from a 
preserved and enhanced concentration of bone union-
related growth factors by achieving increased and 
enhanced structure of the remodeled bone. FD-PRP 
could be of great use in our ageing society, which leads 
to an increased number of spinal pathology patients 
requiring spinal fusion surgery. 
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